[ad_1]
It is currently unclear whether the disease was caused by the vaccine or not and no further information on the adverse reaction was provided.
As had already happened with AstraZeneca, Johnson & Johnson is now also forced to stop, at least temporarily, the phase 3 study of its Covid-19 candidate vaccine. An “unexplained illness” developed in one of the volunteers who received the drug. It is currently unclear whether the disease was caused by the vaccine or not and no further information on the adverse reaction was provided. Johnson & Johnson explained that its internal staff and the Independent Data Security Monitoring Board (DSMB) are conducting all appropriate assessments. “Adverse events, such as illnesses or accidents, even serious ones, are part of every clinical study, especially if they are large-scale,” the company clarifies.
The phase 3 study stop
deepening
Coronavirus, where are the vaccines in the world
In the coming days, a committee of experts will analyze the effects caused and the possible relationship between the disease and the composition of the vaccine. The trial stop could last weeks or months. In the worst case, Johnson & Johnson could be forced to start from scratch with a new candidate. The phase 3 study began in September, with the goal of administering the vaccine to at least 60,000 people in the United States and several other countries. The first results were expected by the end of the year or early 2021 at the latest.
The characteristics of the vaccine.
Johnson & Johnson’s experimental vaccine, developed by the Janssen company, is based on a human adenovirus, into which a gene has been grafted that can induce some cells in the human body to produce copies of the spike protein, the main “weapon “. of the coronavirus. This mechanism should cause the immune system to recognize this threat and develop defenses against Sars-CoV-2. This is a solution that has already been tested in the past with other types of vaccines, including one that is effective against the viruses that cause Ebola.
